Table 1.
Population characteristics stratified by any statin use after cohort entry through end of follow-up
| All (n = 2039) | No statin use (n = 1102) | Statin use any time after cohort entry (n = 937) | ||||
|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | |
| Year of colon cancer diagnosis | ||||||
| 1995–1999 | 410 | (20.1) | 264 | (24.0) | 146 | (15.6) |
| 2000–2004 | 569 | (27.9) | 302 | (27.4) | 267 | (28.5) |
| 2005–2009 | 579 | (28.4) | 275 | (25.0) | 304 | (32.4) |
| 2010–2014 | 481 | (23.6) | 261 | (23.7) | 220 | (23.5) |
| Age at diagnosis (years) | ||||||
| mean (SD) | 69.9 | (11.6) | 69.6 | (12.7) | 70.2 | (10.1) |
| < 50 | 94 | (4.6) | 73 | (6.6) | 21 | (2.2) |
| 50–59 | 294 | (14.4) | 167 | (15.2) | 127 | (13.6) |
| 60–69 | 530 | (26.0) | 260 | (23.6) | 270 | (28.8) |
| 70–79 | 677 | (33.2) | 327 | (29.7) | 350 | (37.4) |
| 80+ | 444 | (21.8) | 275 | (25.0) | 169 | (18.0) |
| Sex | ||||||
| Female | 1066 | (52.3) | 626 | (56.8) | 440 | (47.0) |
| Male | 973 | (47.7) | 476 | (43.2) | 497 | (53.0) |
| Hispanic ethnicity | ||||||
| Not Hispanic | 1742 | (85.4) | 916 | (83.1) | 826 | (88.2) |
| Hispanic | 93 | (4.6) | 42 | (3.8) | 51 | (5.4) |
| Unknowna | 204 | (10.0) | 144 | (13.1) | 60 | (6.4) |
| Race | ||||||
| White | 1582 | (77.6) | 844 | (76.6) | 738 | (78.8) |
| Black | 70 | (3.4) | 32 | (2.9) | 38 | (4.1) |
| Asian | 66 | (3.2) | 36 | (3.3) | 30 | (3.2) |
| American Indian/Alaska Native | 9 | (0.4) | 3 | (0.3) | 6 | (0.6) |
| Hawaiian/Pacific Islander | 5 | (0.2) | 3 | (0.3) | 2 | (0.2) |
| Multiple race | 19 | (0.9) | 9 | (0.8) | 10 | (1.1) |
| Other/Unknown | 288 | (14.1) | 175 | (15.9) | 113 | (12.1) |
| Smoking before diagnosis | ||||||
| Never | 916 | (45.2) | 538 | (49.1) | 378 | (40.5) |
| Ever | 1112 | (54.8) | 557 | (50.9) | 555 | (59.5) |
| Unknown | 11 | 7 | 4 | |||
| Charlson score at diagnosis | ||||||
| mean (SD) | 0.8 | (1.4) | 0.6 | (1.0) | 1.2 | (1.6) |
| 0 | 1085 | (53.2) | 688 | (62.4) | 397 | (42.4) |
| 1 | 429 | (21.0) | 207 | (18.8) | 222 | (23.7) |
| 2 | 184 | (9.0) | 75 | (6.8) | 109 | (11.6) |
| 3+ | 225 | (11.0) | 65 | (5.9) | 160 | (17.1) |
| Unknowna | 116 | (5.7) | 67 | (6.1) | 49 | (5.2) |
| BMI at diagnosis (kg/m2) | ||||||
| mean (SD) | 27.9 | (5.9) | 27 | (5.6) | 29 | (6.1) |
| Underweight (< 18.5) | 41 | (2.1) | 29 | (2.8) | 12 | (1.3) |
| Normal (18.5–24.9) | 610 | (31.4) | 386 | (37.9) | 224 | (24.3) |
| Overweight (25–29.9) | 702 | (36.2) | 351 | (34.5) | 351 | (38.0) |
| Obese (30–34.9) | 380 | (19.6) | 159 | (15.6) | 221 | (23.9) |
| Morbidly obese (35+) | 208 | (10.7) | 93 | (9.1) | 115 | (12.5) |
| Unknown | 98 | 84 | 14 | |||
| Diagnoses in the year before colon cancer | ||||||
| Diabetes | 400 | (19.6) | 93 | (8.4) | 307 | (32.8) |
| Hyperlipidemia/hypercholesterolemia | 655 | (32.1) | 159 | (14.4) | 496 | (52.9) |
| Hypertension | 1111 | (54.5) | 481 | (43.6) | 630 | (67.2) |
| Stage at colon cancer diagnosis | ||||||
| I | 911 | (44.7) | 457 | (41.5) | 454 | (48.5) |
| IIA | 935 | (45.9) | 523 | (47.5) | 412 | (44.0) |
| IIB | 117 | (5.7) | 78 | (7.1) | 39 | (4.2) |
| IIIA | 76 | (3.7) | 44 | (4.0) | 32 | (3.4) |
| Grade | ||||||
| Grade I | 187 | (9.7) | 89 | (8.5) | 98 | (11.1) |
| Grade II | 1423 | (73.8) | 784 | (75.0) | 639 | (72.4) |
| Grade III | 294 | (15.2) | 158 | (15.1) | 136 | (15.4) |
| Grade IV | 24 | (1.2) | 14 | (1.3) | 10 | (1.1) |
| Unknown, not stated, or N/A | 111 | 57 | 54 | |||
| Cancer treatment received | ||||||
| Chemotherapy | 277 | (13.6) | 170 | (15.4) | 107 | (11.4) |
| Radiation | 30 | (1.5) | 15 | (1.4) | 15 | (1.6) |
| Medication use in the year before colon cancer diagnosisb | ||||||
| Any Statin | 542 | (26.6) | 34 | (3.1) | 508 | (54.2) |
| Atorvastatin | 29 | (1.4) | 1 | (0.1) | 28 | (3.0) |
| Lovastatin | 235 | (11.5) | 13 | (1.2) | 222 | (23.7) |
| Simvastatin | 306 | (15.0) | 20 | (1.8) | 286 | (30.5) |
| Other statin | 22 | (1.1) | 3 | (0.3) | 19 | (2.0) |
| Aspirin | 685 | (34.1) | 280 | (25.9) | 405 | (43.8) |
| Any antihypertensive | 1078 | (52.9) | 444 | (40.3) | 634 | (67.7) |
| Common types of statin use after colon cancer diagnosisb | ||||||
| Atorvastatin | 220 | (10.8) | 0 | (0) | 220 | (23.5) |
| Lovastatin | 425 | (20.8) | 0 | (0) | 425 | (45.4) |
| Simvastatin | 683 | (33.5) | 0 | (0) | 683 | (72.9) |
| Other statin | 101 | (5.0) | 0 | (0) | 101 | (10.8) |
aUnknown categories for race and Charlson score are included in percent calculations because they are included in the multivariable models
bMedication categories not mutually exclusive because patients could have used more than one type of medication before diagnosis and during study follow-up